Literature DB >> 18688089

Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments.

Kurt R Brunden1, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

The discovery that mutations within the tau gene lead to frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) provided direct evidence that tau alterations can lead to neurodegenerative disease. While the presence of tau fibrils and tangles is a common feature of all tauopathies, including Alzheimer's disease (AD), data are emerging from biochemical, cell-based and transgenic mouse studies which suggest that a pre-fibrillar form of pathological tau may play a key role in eliciting central nervous system neurodegeneration and behavioral impairments. Herein we review recent findings that implicate diffusible tau pathology in the onset of neurodegeneration, and discuss the implications of these findings as they relate to tau tangles and possible therapeutic strategies for the treatment of AD and related tauopathies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688089      PMCID: PMC2789426          DOI: 10.3233/jad-2008-14406

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  58 in total

1.  Structure and novel exons of the human tau gene.

Authors:  A Andreadis; W M Brown; K S Kosik
Journal:  Biochemistry       Date:  1992-11-03       Impact factor: 3.162

Review 2.  Characterization of paired helical filaments by scanning transmission electron microscopy.

Authors:  Hanna Ksiezak-Reding; Joseph S Wall
Journal:  Microsc Res Tech       Date:  2005-07       Impact factor: 2.769

3.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model.

Authors:  Bin Zhang; Arpita Maiti; Sharon Shively; Fara Lakhani; Gaye McDonald-Jones; Jennifer Bruce; Edward B Lee; Sharon X Xie; Sonali Joyce; Chi Li; Philip M Toleikis; Virginia M-Y Lee; John Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

Review 4.  Mutations causing neurodegenerative tauopathies.

Authors:  Michel Goedert; Ross Jakes
Journal:  Biochim Biophys Acta       Date:  2005-01-03

5.  Accelerated filament formation from tau protein with specific FTDP-17 missense mutations.

Authors:  P Nacharaju; J Lewis; C Easson; S Yen; J Hackett; M Hutton; S H Yen
Journal:  FEBS Lett       Date:  1999-03-26       Impact factor: 4.124

6.  Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease.

Authors:  Thomas Fath; Jochen Eidenmüller; Roland Brandt
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

7.  Granular tau oligomers as intermediates of tau filaments.

Authors:  Sumihiro Maeda; Naruhiko Sahara; Yuko Saito; Miyuki Murayama; Yuji Yoshiike; Hyonchol Kim; Tomohiro Miyasaka; Shigeo Murayama; Atsushi Ikai; Akihiko Takashima
Journal:  Biochemistry       Date:  2007-03-06       Impact factor: 3.162

8.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

9.  Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules.

Authors:  B Trinczek; J Biernat; K Baumann; E M Mandelkow; E Mandelkow
Journal:  Mol Biol Cell       Date:  1995-12       Impact factor: 4.138

10.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

View more
  66 in total

1.  Three- and four-repeat Tau coassemble into heterogeneous filaments: an implication for Alzheimer disease.

Authors:  Ayisha Siddiqua; Martin Margittai
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

2.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

Review 3.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 4.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

5.  NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy.

Authors:  Yousuf O Ali; Kai Ruan; R Grace Zhai
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

6.  Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory.

Authors:  Julio J Ramirez; Winona E Poulton; Erik Knelson; Cole Barton; Michael A King; Ronald L Klein
Journal:  Behav Brain Res       Date:  2010-08-19       Impact factor: 3.332

7.  Accelerated neurodegeneration through chaperone-mediated oligomerization of tau.

Authors:  Laura J Blair; Bryce A Nordhues; Shannon E Hill; K Matthew Scaglione; John C O'Leary; Sarah N Fontaine; Leonid Breydo; Bo Zhang; Pengfei Li; Li Wang; Carl Cotman; Henry L Paulson; Martin Muschol; Vladimir N Uversky; Torsten Klengel; Elisabeth B Binder; Rakez Kayed; Todd E Golde; Nicole Berchtold; Chad A Dickey
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

8.  The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus.

Authors:  Jeroen J M Hoozemans; Elise S van Haastert; Diana A T Nijholt; Annemieke J M Rozemuller; Piet Eikelenboom; Wiep Scheper
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

Review 9.  Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

Authors:  Kurt R Brunden; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore
Journal:  Bioorg Med Chem       Date:  2013-12-30       Impact factor: 3.641

Review 10.  Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Authors:  Jennifer N Rauch; Steven H Olson; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.